Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00914823 · ClinicalTrials.gov registry record · Phase 1

Kisspeptin Administration in the Adult

A Phase 1 study, sponsored by Massachusetts General Hospital.

Completed
Registry status
Phase 1
Development phase
256
Enrollment target

NCT00914823: Completed Phase 1 study, sponsored by Massachusetts General Hospital.

NCT00914823 is a Phase 1 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 256 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (327% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT00914823, a Phase 1 study, has completed, sponsored by Massachusetts General Hospital.

COMPLETED
Registry status
Phase 1
Development phase
256 participants
Enrollment target

Study Summary

The goal of this study is to learn about the role of kisspeptin in the reproductive system. Kisspeptin is a naturally occurring hormone in humans that causes the release of other hormones, including gonadotropin-releasing hormone (GnRH) in the body.

Interventions

  • DRUG kisspeptin 112-121
  • DRUG GnRH

Trial Details

FieldValue
Enrollment Target 256 participants
Start Date 2009-06-23
Est. Completion 2021-10-22
Phase Phase 1
Massachusetts General Hospital

2,032 total trials

What the finished NCT00914823 record still lists

NCT00914823 is an interventional study that assigns participants to a tested intervention. The registered 256 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (327% higher).

The record links to 0 conditions, and to 2 interventions - of which kisspeptin 112-121 is the first listed.

NCT00914823 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00914823 about?

NCT00914823 is a clinical study titled "Kisspeptin Administration in the Adult". The goal of this study is to learn about the role of kisspeptin in the reproductive system. Kisspeptin is a naturally occurring hormone in humans that causes the release of other hormones, including gonadotropin-releasing hormone (GnRH) in the body.

What is the current status of trial NCT00914823?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 256 participants. The study started on 2009-06-23. Estimated completion is 2021-10-22.

What interventions are being tested in trial NCT00914823?

The interventions under investigation include: kisspeptin 112-121 (DRUG), GnRH (DRUG).

Who is sponsoring clinical trial NCT00914823?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00914823's enrollment target sits among peer trials

256 168th of 2000 higher than 1,833 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02464696 · 256 participants · NA

    Non-invasive Ventilation in Reducing the Need for Intubation in Patients With Cancer and Respiratory Failure

  • NCT03793062 · 256 participants

    Genetic and Epigenetic Basis of Chronic Wounds

  • NCT04322318 · 256 participants · Phase 2

    A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

  • NCT04468360 · 256 participants · Phase 2

    Facilitation of Extinction Retention and Reconsolidation Blockade in PTSD

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT00914823, the US trial registry maintained by the National Library of Medicine. NCT00914823 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.